The GM of France for Bristol-Myers Squibb (BMS) discusses becoming a “diversified biopharma company”, their commitment to remaining a model of excellence for other affiliates, and his personal philosophy of leadership, moulded by two decades of international experience.
You started off your term with a restructuring plan for the French affiliate in 2013. It is always challenging to lay off employees, but what have been the positive effects of streamlining the business in terms of future performance and efficiency?
Bristol-Myers Squibb’s transformation can be summarized in the phrase “to build a diversified biopharma company”
